Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.52 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487476 | 0.83 | TRPM8 (0.61) | GABBR2GABBR1GABRR1TRPM8 | |
| SCHEMBL29240388 | 0.81 | TRPM8 (0.59) | GABBR2GABBR1GABRR1TRPM8 | |
| SCHEMBL2171778 | 0.81 | TRPM8 (0.43) | CYP1A2MEN1KMT2ATRPM8 | |
| SCHEMBL2353070 | 0.80 | CYP1A2 (0.57) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL6356256 | 0.80 | GABBR2 (0.57) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL6354585 | 0.78 | CYP1A2 (0.55) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL2487479 | 0.78 | TRPM8 (0.48) | TRPM8 | |
| Hydrochloric Acid SCHEMBL9340197 | 0.77 | LMNA (0.56) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL1360213 | 0.76 | TRPM8 (0.41) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL6351470 | 0.75 | CYP1A2 (0.52) | CYP1A2MEN1KMT2AGABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9035088-B2 | Method for producing mono-aminofunctionalized dialkylphosphinic acids and esters and salts thereof by means of acrylnitriles and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-05-19 | — | — | US | disclosed |
| CN-102186866-B | Method for producing mono amino-functionalised dialkylphosphinite acids esters and salts and use thereof | CLARIANT INT LTD | 2015-04-29 | — | — | CN | disclosed |
| EP-2373666-B1 | METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2014-09-24 | — | — | EP | disclosed |
| US-8604232-B2 | Method for producing monoamino-functionalised dialkylphosphinite acids esters and salts and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-10 | — | — | US | disclosed |
| EP-2352741-B1 | METHOD FOR PRODUCING MONO AMINO-FUNCTIONALISED DIALKYLPHOSPHINITE ACIDS ESTERS AND SALTS AND USE THEREOF | CLARIANT INT LTD (CH) | 2013-08-28 | — | — | EP | disclosed |
| EP-2373666-A1 | METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | Clariant Finance (BVI) Limited (VG) | 2011-10-12 | — | — | EP | disclosed |
| US-20110213061-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213078-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213079-A1 | Method for Producing Monoamino-Functionalised Dialkylphosphinite Acids Esters and Salts and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| EP-2352741-A1 | METHOD FOR PRODUCING MONO AMINO-FUNCTIONALISED DIALKYLPHOSPHINITE ACIDS ESTERS AND SALTS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010051892-A1 | METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051894-A1 | METHOD FOR PRODUCING MONO AMINO-FUNCTIONALISED DIALKYLPHOSPHINITE ACIDS ESTERS AND SALTS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213078-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof | AOC2, AOC3, DAO | CYP1A2 969/4885MEN1 3699/4885KMT2A 2729/4885 |
| US-20110213079-A1 | Method for Producing Monoamino-Functionalised Dialkylphosphinite Acids Esters and Salts and Use Thereof | DAO, HAO2, AOC1 | CYP1A2 1584/4885MEN1 2350/4885KMT2A 1612/4885 |
| US-20110213061-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof | HAO2, ACSL1, ACSL3 | CYP1A2 1444/4885MEN1 3168/4885KMT2A 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.